Navigation Links
AMDL, Inc. Completes Revision of Performance & Equity Incentive Compensation Plan
Date:1/8/2009

TUSTIN, Calif., Jan. 8 /PRNewswire-FirstCall/ -- AMDL, Inc. (NYSE Alternext US: ADL), a vertically integrated pharmaceutical company with operations in China and the U.S., announced today it has revised its 2009 Performance and Equity Incentive Compensation Plan for senior management and employees.

Under the terms of the Plan, AMDL has transitioned from a "discretionary cash and options-based bonus plan" to a performance-based, stock and cash incentive plan. Incentives are based on successfully achieving financial targets established by AMDL's Board of Directors.

Plan highlights include:

  • Performance based incentive awards
  • Board-determined quarterly income performance targets
  • Limited cash bonus awards
  • Reaffirmation of AMDL's commitment to not issue discretionary incentive awards

According to Mr. Michael Boswell, independent board member and Chairman of AMDL's Compensation and Audit Committees, "We have made a deliberate decision to establish a more structured compensation plan that directly links our executive and employee compensation to Company performance. In establishing this new plan, we are creating stronger alignment between the interests of our management team, employees, and investors. We feel the modifications made support AMDL's long-term success."

Under AMDL's 2009 Performance and Equity Incentive Compensation Plan, all stock granted to senior executives and employees as incentive compensation will be scheduled to vest only if the Company's meets its strategic goals and specific financial performance targets. AMDL's Board of Directors and Compensation Committee have reviewed and approved the performance targets and Plan outlined above. Detailed information on this revised Plan can be found in AMDL's Form 8-K filed with the Securities and Exchange Commission.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    kszarkowitz@amdl.com
    (Tel :) 206. 310.5323


'/>"/>
SOURCE AMDL, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Research Report
2. AMDL, Inc. Selected as #1 Small-Cap Stock Pick for 2009
3. Ambulatory Services of America, Inc. Completes Purchase of Majority Interest in Rosa of Georgia, LLC
4. Kentucky Medical Services Foundation Completes Successful Charge Capture Technology Conversion
5. Escalon(R) Medical Corp. Completes Bolt-On Acquisition, Enhances Market Position in France and Expands Product Offering
6. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
7. Blue Cross and Blue Shield of Florida Completes Acquisition of Florida Health Care Plans
8. Hard To Treat Diseases (HTDS) Completes E Europe Merger
9. New Zealand Waynes New Resources Development Co., Ltd. Completes Reverse Merger to Go Public in the U.S.
10. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
11. Smart Financial Credit Union Completes Key FCU Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , Sept. ... Penn. , and OptiMed Specialty Pharmacy of ... partnership to offer a strategic hub service that expedites ... highly sought-after personal spirometer, Spiro PD 2.0, and wellness ... A spirometer is a medical device used to measure ...
Breaking Medicine Technology: